This remarkable increase from 17 in 2021 ranks among the fastest for pharmaceutical companies, establishing Lupin as a leader in sustainable growth
Treatment with Verzenio also resulted in sustained invasive disease-free survival and distant relapse-free survival benefit
This achievement underscores the company’s steadfast commitment to sustainability, corporate responsibility, and ESG excellence
Biocon’s subsidiary Biocon Biologics Limited, which also participated independently in the assessment for the first time, reported an S&P Global ESG Score of 53
The new Beyfortus data are consistent with all data accumulated to date and confirm its strong profile
48-week data from MOMENTUM phase III clinical trial show momelotinib maintained total symptom response
By 2025, the company plans to achieve carbon and water neutrality, zero-waste to landfill, anti-microbial resistance stewardship and green chemistry
Innovative TIMScore for dda-PASEF and dia-PASEF libraries, combined with TIMS DIA-NN identifies 9000 protein groups from 200 ng K562 lysate in just 35 min gradient
Clears major obesity endpoints at 80 weeks
All three dose levels, 4 mg, 9 mg and 12 mg, successfully met the primary and key secondary endpoints in 80 weeks
Subscribe To Our Newsletter & Stay Updated
